TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with established cirrhosis complicated by hepatic encephalopathy~* For the purposes of this study a patient will be considered to have cirrhosis if they fulfil two out of the three diagnostic criteria of confirmatory liver histology, biochemistry and/or radiologic findings consistent with cirrhosis/portal hypertension, and~* are presenting with chronic persistent overt hepatic encephalopathy (≥ grade 1) or with ≥2 episodes of overt hepatic encephalopathy in the previous 6 months.~Exclusion Criteria:~* Age ≤18 or ≥75.~* Evidence of disseminated malignancy.~* Known coeliac or inflammatory bowel disease.~* Evidence of intestinal failure, intestinal obstruction and / or previous bowel resection.~* Pre-existing immunosuppressive states including HIV infection and chronic granulomatous diseases.~* Anti-inflammatory drug use e.g non-steroidals and immunomodulatory drug use e.g. prednisolone and azathioprine.~* Known hypersensitivity to rifaximin or rifamycin-derivatives~* Already receiving concomitant oral or parenteral antibiotic therapy e.g norfloxacin.~* Infection with clostridium difficile or stool testing positive for clostridium difficile toxin in the previous 3 months.~* Pregnancy or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin-α (Type: ACTIVE_COMPARATOR): Rifaximin-α (TARGAXAN TM, manufactured by Alfa-Wasserman, Bologna, Italy) tablets - 550mg twice daily for 90 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets - 550mg twice daily for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Cancer Detection Test - Lung Cancer Scotland

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant is willing and able to give informed consent for participation in the study~2. Male or female aged 50 years to 75 years~3. Current or Ex-smoker with at least 20 year pack history~4. or Less than 20 year pack history but with family history of lung cancer in a 1st degree relative (mother, father, sister, brother, child)~5. ECOG Status: 0, 1 and 2 (Eastern Co-operative Oncology Group) Grade ECOG 0 Fully active, able to carry on all pre-disease performance without restriction 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work 2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours~6. Geographical postal sectors of:~NHS Geographical Area Eligible Postcodes Tayside DD1 - DD11, PH1-PH3 , PH6-PH8, PH10, PH11, PH13, PH15 \& PH16 Greater Glasgow \& Clyde G1-G5, G11 -G15, G20-G22, G31-34, G40 -G46, G51- G53, G60-G62 \&G64, G66 \& G69, G72 \& G73, G76-G78, G81-G83 PA1-PA8 (except PA6), PA11-PA16 \& PA19~Exclusion Criteria:~1. History of any cancer other than non-melanomatous skin cancer, cervical cancer in situ.~2. Symptoms suggestive of lung cancer within past 6 months (haemoptysis, unintentional weight loss (at least 5% in preceding 6 months).~3. Patients for whom the GP considers invitation to the study would cause undue distress.~4. Patients with other terminal disease.~5. Patients on prolonged / continuous use (\> 3months) of cytotoxic/ immuno-suppressant drugs eg: Cyclophosphamide. Monotherapy using glucocorticoids/ steroids eg prednisolone is NOT an exclusion criteria.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): participants monitored for 10 years for lung cancer incidence.
- Early CDT Lung Test (Type: ACTIVE_COMPARATOR): Early CDT lung blood test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female diagnosed with idiopathic PD, without any known cause for Parkinsonism.~2. If female and of childbearing potential, subject should be abstinent or continuing to practice and willing to continue throughout the study with appropriate contraceptives (defined as Nova ring, oral, injected, transdermal patch, implanted, or barrier). The subject must agree to take every precaution to ensure that pregnancy will not occur during the study.~3. At least 30 years old at the time of diagnosis of PD.~4. Mini Mental State Examination (MMSE) ≥ 26 at Screening Visit.~5. A responder to LD and currently being chronically treated with stable dosage of commercially available standard, orally disintegrating, or controlled-release CD LD for at least 1 month.~6. Must have predictable fluctuations between on and off states.~7. Hoehn and Yahr Stage I-IV when on.~8. Able to provide informed consent and willing to sign Health Insurance Portability and Accountability Act (HIPAA) authorization.~9. Able and willing to comply with the protocol, including availability for all scheduled study visits and blood sample collections.~Exclusion Criteria:~1. Pregnant or breastfeeding.~2. Diagnosed with atypical parkinsonism.~3. History, physical findings or laboratory results suggesting a diagnosis other than PD.~4. Allergic or nonresponsive to previous CD-LD therapy.~5. Any medical (e.g., liver or kidney impairment, peptic ulcer) or condition/history that, in the Investigator's opinion, may jeopardize the subject's safety.~6. Exposure to any investigational agent within 30 days prior to Visit 1.~7. Donated blood or plasma within 28 days.~8. Had prior functional neurosurgical treatment for PD (ablation or Deep Brain Stimulation).

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: OTHER): Treatment Period 1:~IPX066 - 7 days; Washout Period - 7 days;~Treatment Period 2:~IR CD-LD- 7 days
- Sequence 2 (Type: OTHER): Treatment Period 1:~IR CD-LD - 7 days; Washout period - 7 days;~Treatment Period 2:~IPX066- 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core study on SC or IV TCZ and, based on the Investigator's judgment, may continue to benefit from TCZ treatment in this study investigating the SC formulation~* Receiving treatment on an outpatient basis~* Females of childbearing potential and males with female partners of childbearing potential must agree to use reliable means of contraception as defined by protocol~Exclusion Criteria:~* Premature withdrawal from WA22762 (NCT01194414) or NA25220 (NCT01232569) core studies for any reason~* History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies~* Evidence of serious uncontrolled concomitant disease or disorder~* Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections~* Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening~* History of or currently active primary or secondary immunodeficiency~* Oral corticosteroids at greater than (\>) 10 mg per day prednisone or equivalent, or non-steroidal anti-inflammatory drugs (NSAIDs) above the maximum recommended dose~* Intra-articular or parenteral corticosteroids within 4 weeks prior to Baseline~* Treatment with any investigational or commercially available biologic disease-modifying anti-rheumatic drug (DMARD) other than TCZ at any time between completion of the core study WA22762 (NCT01194414) or NA25220 (NCT01232569) and enrollment in the long-term extension study~* Pregnant or breastfeeding women~* History of alcohol, drug, or chemical abuse within 1 year prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SC TCZ QW (Type: EXPERIMENTAL): Participants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
- SC TCZ Q2W (Type: EXPERIMENTAL): Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of type 1 diabetes for up to 3 months at screening~* Insulin dependency~* Fasting C-peptide levels \>= 0.22 nmol/L~* Presence of at least 1 of the diabetes-related autoantibodies (IA-2A, GAD or IA)~Exclusion Criteria:~* Pregnancy or intent to conceive in the next 2 years~* Significant diseases that could affect response to treatment, such as tumors, psychiatric disorders, substance abuse, severe allergies or diabetes-related complications.~* Patient has immune deficiency or receives immuno-suppressive or cytotoxic drugs.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- DiaPep277 (Type: EXPERIMENTAL): DiaPep277 1.0 mg + 40 mg Mannitol in 0.5 mL lipid emulsion.
- Placebo (Type: PLACEBO_COMPARATOR): Mannitol 40 mg in 0.5 mL lipid emulsion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Response to Warfarin in Healthy Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult (\> 18 years old.) subjects not taking warfarin~* Willing and able to grant written informed consent~* Available in proximity to the Medical Center for the anticipated duration of data collection (approximately 3 weeks).~* Pre-menopausal women required negative pregnancy test at study onset and willingness to abstain from sexual activity or use barrier contraception; oral contraceptives interfere with coumadin.~Exclusion Criteria:~* Daily prescribed medications including (1) a medication known to interact with warfarin, based on interactions listed in Micromedex as moderate or severe, and probable or definite (as of study start date, Appendix A) (2) aspirin or clopidogrel, which may increase bleeding risk in combination with warfarin.~* Recent therapy (within two weeks) with a medication known to interact with warfarin based on medication interactions listed in Micromedex~* History of thrombotic disorder requiring anticoagulant therapy~* Thrombophilia or coagulopathy, by history or screening coagulation profile with INR or PTT level \> 2x the upper limit of normal~* Family history of thrombophilia or coagulopathy; prisoners or wards of the state; scheduled elective surgery within one month~* Active liver disease based on clinical history or serum transaminase levels \> 2x the upper limit of normal~* Protein C or S Deficiency assessed on screening protein C and S activity profile~* Age ≥ 75~* Pre-menopausal women on oral contraception~* Non-English speaking individuals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Warfarin (Type: EXPERIMENTAL): Healthy subjects age 18-74 with no medical indication for warfarin therapy, who are free of medications and co-morbid medical conditions with the potential to interfere with warfarin metabolism, and who are willing to follow a fixed vitamin K diet (men 120 micrograms/day, women 90 micrograms/day) are included.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be eligible for this study, subjects must fulfill all of the following criteria:~1. Male or female ≥12 years of age.~2. A clear diagnosis of acne vulgaris, defined as ≥20 acne inflammatory and/or non-inflammatory lesions (≥10 of the acne lesions must be on the face, the others may be present on the neck, shoulders, upper chest, and upper back) at screening.~3. A diagnosis of G6PD deficiency, defined as having a G6PD value below the lower limit of normal for the central reference laboratory.~Exclusion Criteria:~Subjects meeting any of the following criteria will be excluded from the study:~1. A dermal examination reveals the presence of severe cystic acne or acne conglobata.~2. Treatment with isotretinoin (Accutane®) within 3 months of baseline and throughout the study.~3. Subjects predisposed to anemia for other medical reasons, including but not limited to gastrointestinal bleeding and cancer.~4. Subjects who are using topical or systemic medications for acne throughout the study. This includes, but is not limited to, benzoyl peroxide, antibiotics, topical Vitamin A derivatives such as Retin-A.~5. Subjects who are using medication or eating foods that could potentially cause a hemolytic event in individuals with G6PD deficiency during the study.~6. Facial surgery (dermabrasion, laser resurfacing or other facial cosmetic surgeries) within 3 months of baseline and throughout the study.~7. A history of hypersensitivity to dapsone, parabens, or any component of the study products.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anakinra as a Treatment for Hydradenitis Suppurativa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1) Signed informed consent form with Confirmed diagnosis of hidradenitis suppurativa with moderate or severe disease activity~Exclusion Criteria:~1. Use of the following therapies:~   * Etanercept in the 4 weeks prior to the baseline visit (Day 1)~  * Adalimumab in the 8 weeks prior to the baseline visit (Day 1)~  * Infliximab in the 12 weeks prior to the baseline visit (Day 1)~  * Any other investigational biologics in the 8 weeks prior to the baseline visit (Day 1)~  * Leflunomide in the 4 weeks prior to the baseline visit (Day 1) • Thalidomide in the 4 weeks prior to the baseline visit (Day 1)~  * Cyclosporine in the 4 weeks prior to the baseline visit (Day 1)~  * I.V. immunoglobulin (I.V. Ig) in the 8 weeks prior to the baseline visit (Day 1)~  * 6-Mercaptopurine, azathioprine, cyclophosphamide, or chlorambucil in the 12 weeks prior to the baseline visit (Day 1)~  * Colchicine, dapsone, mycophenolate mofetil \& systemic antibiotics in the 3 weeks prior to the baseline visit (Day 1)~  * Corticosteroids 20mg/day or \>0.4 mg/kg, whichever applies, in the 1 week prior to the baseline visit (Day 1)~2. history of immunocompromise including HIV infection~3. positive Hep B surface antigen -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): All patients in this arm will receive the investigation drug anakinra once daily subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients receiving Tofacitinib (Xeljanz)~Exclusion Criteria:~Not Applicable

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Xeljanz) (Type: None): Tablets 5 mg BID
- Standard of Care (Type: None): Standard of Care for Rheumatoid Arthritis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Crochet Octopus in The Process of Heel Lance in Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* being a healthy term neonates,~* being 5-15 days,~* taking of blood sample for Guthrie test routinely.~Exclusion Criteria:~* admitted to the neonatal intensive care units~* his/her being taken any analgesics prior to the intervention,~* having any congenital anomalies

- Gender: ALL
- Minimum Age: 5 Days
- Maximum Age: 15 Days
- Healthy Volunteers: t

Study Arms:
- Experimental Group (Type: EXPERIMENTAL): Crochet octopus was delivered to the hands of the neonates in the experimental group 10 minutes before heel lance process and they were contacted with the crochet octopus up to 10 minutes after the procedure.
- Control Group (Type: NO_INTERVENTION): Control group neonates were performed all the process without delivering them any crochet octopus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post Extubation Delirium and End-tidal Sevoflurane Concentration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 2-7 years~* ASA I - II~* Estimated surgery time \< 2 hours~* Sevoflurane induction and maintenance along with caudal block or Axillary Block~Exclusion Criteria:~* Craniofacial anomalies~* Difficult exposure of the vocal cordS~* Obesity~* Asthma~* Invalid caudal block or axillary block

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- low concentration (LC) (Type: EXPERIMENTAL): low concentration group
- high concentration (HC) (Type: EXPERIMENTAL): high concentration group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a history of stable intermittent claudication lasting more than 6 months before Screening.~2. Has a diagnosis of peripheral arterial disease (PAD) (Code I70.2 according to the international classification of diseases-10th revision) Fontaine Stage IIB confirmed by ultrasound color duplex imaging.~3. Has a resting Doppler ankle-brachial index of less than or equal to (\<=) 0.9.~4. Has intermittent claudication with initial claudication distance (ICD) less than (\<) 200 meters.~5. Is not newly diagnosed with PAD and has a history of stable PAD therapy for at least 2 weeks before Screening.~Exclusion Criteria:~1. Has PAD Fontaine Stage III or IV (pain at rest, non-healing ulceration, or gangrene).~2. Has evidence of nonatherosclerotic PAD.~3. Has greater than (\>) 25 percent (%) variability in absolute claudication distance (ACD) based on treadmill testing during the screening period.~4. Has lower extremity arterial reconstruction (surgical or endovascular) or sympathectomy within 3 months before Screening.~5. Is eligible for surgical/interventional reconstruction.~6. Had a myocardial infarction or major cardiac surgery within 3 months before Screening.~7. Has congestive heart failure (New York Heart Association Class III/IV).~8. Has uncontrolled diabetes mellitus (glycosylated hemoglobin \[HbA1c \>9%\]) or diabetic polyneuropathy.~9. Has any other illness that significantly limits exercise capacity or other medical condition, including any psychiatric disorder that limits participation (in the judgement of the investigator).~10. The subject has received any prohibited medication within 14 days before Randomization (Day 1)~11. The subject is undergoing the supervised exercise training program by the time of Screening and is going to continue this program due to its effectiveness.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Actovegin 1200 mg (Type: EXPERIMENTAL): Actovegin 1200 milligram (mg), intravenously, once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (TID) (1200 mg/day) for up to 10 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Actovegin placebo-matching, intravenously, once daily for up to 2 weeks and actovegin placebo-matching tablets, orally, TID for up to 10 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete